Business
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018 ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n\n\n\n\n\n\nMedicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2018\nCanada NewsWire\nTORONTO and HOUSTON, April 25, 2018\n\n\n\nTORONTO and HOUSTON, April 25, 2018 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman, President and CEO and Ms. Elizabeth Williams, CFO, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.\n\nDetails of the presentation are as follows:\n\n\n\n\nDate: \n\n\n Wednesday, May 2, 2018\n\n\n\nTime: \n\n\n 11:00 am ET\n\n\n\nLocation: \n\n\n Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada\n\n\nAbout the Conference:The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.\n\nAbout Medicenna Therapeutics Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Medicenna is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. A Phase 2b clini...